Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Research & Development (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Research & Development for 16 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 52.42% year-over-year to $1.8 million, compared with a TTM value of $12.7 million through Dec 2025, changed 0.48%, and an annual FY2025 reading of $12.7 million, changed 0.48% over the prior year.
  • Research & Development was $1.8 million for Q4 2025 at Catalyst Pharmaceuticals, down from $2.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $83.7 million in Q3 2023 and bottomed at $1.8 million in Q4 2025.
  • Average Research & Development over 5 years is $7.8 million, with a median of $3.8 million recorded in 2024.
  • The sharpest move saw Research & Development soared 906.76% in 2023, then crashed 96.07% in 2024.
  • Year by year, Research & Development stood at $5.0 million in 2021, then fell by 18.01% to $4.1 million in 2022, then tumbled by 51.82% to $2.0 million in 2023, then skyrocketed by 92.6% to $3.8 million in 2024, then plummeted by 52.42% to $1.8 million in 2025.
  • Business Quant data shows Research & Development for CPRX at $1.8 million in Q4 2025, $2.7 million in Q3 2025, and $4.4 million in Q2 2025.